The study is meant to reveal whether a shorter treatment using a new combination of four different antibiotics could be as effective as the regular, longer treatment for tuberculosis (TB).If this research, named SimpliciTB, turns out successful, the treatment period for drug-sensitive tuberculosis could be reduced from six to four months, and the treatment of drug-resistant tuberculosis could go down from 18-24 months to six months.
Shorter treatmentA shorter treatment of TB brings several significant advantages. If the patient is cured faster, the period of contagiousness to others will also be shorter, which will also decrease the chance of the disease spreading. Additionally, it helps increase the patients’ compliance. The access to hospitals and proper medical care in the countries where TB occurs is often limited, which frequently puts the therapy compliance at stake in longer-term treatments. The shorter the treatment, the better the chances are of a patient finishing it. In the case of TB, completing the entire course of treatment is crucial. Mediocre therapy compliance can result in an increased resistance of the bacteria.
Radboud university medical center’s roleThe study is a global initiative of the TB Alliance. The Sub-Saharan African part of the study is carried out by PanACEA, a consortium of 16 institutes in 11 countries, coordinated by Martin Boeree and Rutger Spoor from the department of Pulmonary Diseases at Radboud university medical center. PanACEA received 12 million euros for this study, of which 1.6 million euros is made available to Radboud university medical center. Radboud university medical center takes on the management and medical monitoring and will work on the research capacity development of the African partners.
Capacity developmentThe continued development of African clinical research centers is a priority of the PanACEA consortium. Its aim is to get these centers to a higher level and keep them there and to have their clinical research meet the highest quality requirements, such as those of the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This will put African centers in a position in which they will be able to lead future research. Aspects of capacity development include the development of infrastructure, admission facilities, laboratories and drugstores, but also the scientific support of PhD candidates and postdocs.
About tuberculosisTuberculosis is a prevalent infectious disease. About 2.3 billion people around the world have a latent infection, and 10 million new patients develop the active disease each year. Tuberculosis is caused by the Mycobacterium tuberculosis bacteria. These bacteria penetrate the cells and can become encased there. During this process, the tissue can get damaged, which leads to the disease. Tuberculosis generally affects the lungs but can also affect other parts of the body.
Related news items
People-like-me treatment for intermittent claudication Personalized approach for patients27 February 2020
Radboudumc, with the University of Colorado, ClaudicatioNet and Harteraad, has developed a method to better treat people with intermittent claudication. This method, by RIHS researcher Thomas Hoogeboom among others, enables physiotherapists to coordinate the care process with the patient better.read more
Guiding the surgeon real-time tumor visualization during surgery26 February 2020
Incomplete excision of tumor tissue negatively affects the prognosis of the patient. RIHS researcher Mark Rijpkema and colleagues are working on the development of new dual-labeled tracers and currently are implementing this into the clinic.read more
Jurgen Fütterer appointed Professor of Image-Guided Oncological Interventions26 February 2020
RIHS researcher Fütterer is an interventional radiologist and an expert in the field of cancer imaging techniques, image-guided interventions and robotics. He is also Professor at the Robotics and Mechatronics Group at the University of Twente.read more